BAGSVAERD, Denmark, March 31, 2006 (PRIMEZONE) -- Following a change in the distribution of responsibilities among the members of its Executive Management, Novo Nordisk has reduced the number of executives from six to five. In this connection Executive Vice President Lars Almblom Joergensen leaves Novo Nordisk by mutual agreement. His areas of responsibility, Quality, Regulatory Affairs and Business Development, will be taken over by Lise Kingo, Mads Krogsgaard Thomsen and Jesper Brandgaard, respectively. The changes take effect from today.
Commenting on the changes, Lars Rebien Soerensen, president and CEO, says: "I would like to express my sincere gratitude to Lars Almblom Joergensen for his significant contribution to the company during his more than 25 years with Novo Nordisk. He has played a major role in the company's successful development over the years and is highly respected throughout the organisation for his professionalism and integrity. I wish him the best of luck in the future."
Accordingly, Novo Nordisk's Executive Management is now composed as follows:
- Lars Rebien Soerensen, president and CEO (chief executive officer). - Jesper Brandgaard, executive vice president and CFO (chief financial officer), responsible for finance, legal, IT and corporate and business development. - Lise Kingo, executive vice president and chief of staffs, responsible for corporate staffs, including people, communication and quality. - Kare Schultz, executive vice president and COO (chief operating officer), responsible for sales, marketing and production. - Mads Krogsgaard Thomsen, executive vice president and chief science officer, responsible for research, development and regulatory affairs.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 22,000 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
Stock Exchange Announcement No 15 / 2006